{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T16:54:53Z","timestamp":1787849693713,"version":"build-2784847793"},"reference-count":122,"publisher":"Bioscientifica","issue":"3","license":[{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":272,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Anaplastic thyroid carcinoma (ATC) is among the most daunting entities in clinical oncology. Large-scale genomic studies of thyroid cancer within the last decade have uncovered a distinct set of recurrent somatic alterations implicated in the development, aggressiveness, and treatment resistance of ATC. The sequence of events leading to the development of ATC commonly begins with a tumorigenic mutation that constitutively activates the mitogen-activated protein kinase (MAPK) pathway, giving rise to indolent entities such as well-differentiated papillary or follicular thyroid carcinomas. This is followed by recurring alterations that drive oncogenic properties such as enhanced proliferation, genomic instability, replicative immortality, and dedifferentiation, culminating in the emergence of highly aggressive ATC tumors. The truncal MAPK-activating events present therapeutic opportunities, as small molecule inhibitors against key components of this pathway are available. Indeed, genotype-guided targeting of the MAPK pathway is now the standard of care for subgroups of ATC patients, and further efforts exploring additional MAPK inhibitors and the combination of immune checkpoint blockade with MAPK inhibition are overcoming resistance to the current targeted therapies in the clinic and expanding our arsenal against this disease. In this review, we summarize the current understanding of the genomic landscape of ATC, discuss the biological and clinical ramifications of recurring aberrations, and provide an overview of the opportunities and challenges in the clinical management of this lethal malignancy.<\/jats:p>","DOI":"10.1530\/etj-25-0057","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T09:43:26Z","timestamp":1747820606000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-17","source":"Crossref","is-referenced-by-count":12,"title":["NOVEL INSIGHTS IN ADVANCED THYROID CARCINOMA: FROM MECHANISMS TO TREATMENTS: Molecular insights into the origin, biology, and treatment of anaplastic thyroid carcinoma"],"prefix":"10.1530","volume":"14","author":[{"given":"Amir Hossein","family":"Karimi","sequence":"first","affiliation":[{"name":"Department of Otolaryngology \u2013 Head & Neck Surgery, Western University 1 , , ,","place":["London, Ontario, Canada"]},{"name":"Department of Pathology and Laboratory Medicine, Western University 2 , , ,","place":["London, Ontario, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter YF","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology \u2013 Head & Neck Surgery, Western University 1 , , ,","place":["London, Ontario, Canada"]},{"name":"Department of Pathology and Laboratory Medicine, Western University 2 , , ,","place":["London, Ontario, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Cecchini","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Western University 2 , , ,","place":["London, Ontario, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W","family":"Barrett","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology \u2013 Head & Neck Surgery, Western University 1 , , ,","place":["London, Ontario, Canada"]},{"name":"Department of Oncology, Western University 3 , , ,","place":["London, Ontario, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harrison","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology \u2013 Head & Neck Surgery, Western University 1 , , ,","place":["London, Ontario, Canada"]},{"name":"Department of Pathology and Laboratory Medicine, Western University 2 , , ,","place":["London, Ontario, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengjie","family":"Ying","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology \u2013 Head & Neck Surgery, Western University 1 , , ,","place":["London, Ontario, Canada"]},{"name":"Department of Pathology and Laboratory Medicine, Western University 2 , , ,","place":["London, Ontario, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nhi","family":"Le","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology \u2013 Head & Neck Surgery, Western University 1 , , ,","place":["London, Ontario, Canada"]},{"name":"Department of Pathology and Laboratory Medicine, Western University 2 , , ,","place":["London, Ontario, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe S","family":"Mymryk","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology \u2013 Head & Neck Surgery, Western University 1 , , ,","place":["London, Ontario, Canada"]},{"name":"Department of Oncology, Western University 3 , , ,","place":["London, Ontario, Canada"]},{"name":"Department of Microbiology & Immunology, Western University 4 , , ,","place":["London, Ontario, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie E","family":"Ailles","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre, University Health Network 5 , , ,","place":["Toronto, Ontario, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0760-980X","authenticated-orcid":true,"given":"Anthony C","family":"Nichols","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology \u2013 Head & Neck Surgery, Western University 1 , , ,","place":["London, Ontario, Canada"]},{"name":"Department of Oncology, Western University 3 , , ,","place":["London, Ontario, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2025,5,21]]},"reference":[{"key":"2026070712532795200_bib1","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1089\/thy.2020.0944","article-title":"2021 American Thyroid Association Guidelines for management of patients with anaplastic thyroid cancer: American thyroid Association anaplastic thyroid cancer guidelines task force","volume":"31","author":"Bible","year":"2021","journal-title":"Thyroid"},{"key":"2026070712532795200_bib2","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1089\/thy.2016.0395","article-title":"Patterns of treatment failure in anaplastic thyroid carcinoma","volume":"27","author":"Rao","year":"2017","journal-title":"Thyroid"},{"key":"2026070712532795200_bib3","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.8722","article-title":"Physician perspectives of overdiagnosis and overtreatment of low-risk papillary thyroid cancer in the US","volume":"5","author":"Dedhia","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2026070712532795200_bib4","first-page":"5888","article-title":"The incidence and survival analysis for anaplastic thyroid cancer: a SEER database analysis","volume":"11","author":"Lin","year":"2019","journal-title":"Am J Transl Res"},{"key":"2026070712532795200_bib5","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.wjorl.2018.05.006","article-title":"Is the incidence of anaplastic thyroid cancer increasing: a population based epidemiology study","volume":"5","author":"Janz","year":"2019","journal-title":"World J Otorhinolaryngol Head Neck Surg"},{"key":"2026070712532795200_bib6","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1001\/jamaoncol.2020.3362","article-title":"Evaluation of overall survival in patients with anaplastic thyroid carcinoma, 2000\u20132019","volume":"6","author":"Maniakas","year":"2020","journal-title":"JAMA Oncol"},{"key":"2026070712532795200_bib7","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1001\/jamaoncol.2024.4729","article-title":"Anti\u2013programmed death ligand 1 plus targeted therapy in anaplastic thyroid carcinoma","volume":"10","author":"Cabanillas","year":"2024","journal-title":"JAMA Oncol"},{"key":"2026070712532795200_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.113826","article-title":"The genomic and evolutionary landscapes of anaplastic thyroid carcinoma","volume":"43","author":"Zeng","year":"2024","journal-title":"Cell Rep"},{"key":"2026070712532795200_bib9","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1172\/JCI85271","article-title":"Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers","volume":"126","author":"Landa","year":"2016","journal-title":"J Clin Investig"},{"key":"2026070712532795200_bib10","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1158\/1078-0432.CCR-18-0373","article-title":"Genetic analysis of 779 advanced differentiated and anaplastic thyroid cancers","volume":"24","author":"Pozdeyev","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2026070712532795200_bib11","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1093\/hmg\/ddu749","article-title":"Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencing","volume":"24","author":"Kunstman","year":"2015","journal-title":"Hum Mol Genet"},{"key":"2026070712532795200_bib12","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1089\/thy.2020.0086","article-title":"Dissecting anaplastic thyroid carcinoma: a comprehensive clinical, histologic, immunophenotypic, and molecular study of 360 cases","volume":"30","author":"Xu","year":"2020","journal-title":"Thyroid"},{"key":"2026070712532795200_bib13","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1038\/s41467-019-10680-5","article-title":"Integrative analysis of genomic and transcriptomic characteristics associated with progression of aggressive thyroid cancer","volume":"10","author":"Yoo","year":"2019","journal-title":"Nat Commun"},{"key":"2026070712532795200_bib14","doi-asserted-by":"crossref","first-page":"e988","DOI":"10.1210\/clinem\/dgab014","article-title":"Novel recurrent altered genes in Chinese patients with anaplastic thyroid cancer","volume":"106","author":"Zhang","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070712532795200_bib15","article-title":"Impact of somatic mutations on survival outcomes in patients with anaplastic thyroid carcinoma","volume":"6","author":"Wang","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"2026070712532795200_bib16","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41698-025-00802-2","article-title":"Genomic landscape and comparative analysis of tissue and liquid-based NGS in Taiwanese anaplastic thyroid carcinoma","volume":"9","author":"Yeh","year":"2025","journal-title":"NPJ Precis Oncol"},{"key":"2026070712532795200_bib17","doi-asserted-by":"crossref","first-page":"42613","DOI":"10.18632\/oncotarget.17300","article-title":"NGS based identification of mutational hotspots for targeted therapy in anaplastic thyroid carcinoma","volume":"8","author":"Tiedje","year":"2017","journal-title":"Oncotarget"},{"key":"2026070712532795200_bib18","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1089\/thy.2016.0254","article-title":"Molecular pathology of anaplastic thyroid carcinomas: a retrospective study of 144 cases","volume":"27","author":"Bonhomme","year":"2017","journal-title":"Thyroid"},{"key":"2026070712532795200_bib19","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1210\/clinem\/dgae271","article-title":"Genomic landscape and clinical features of advanced thyroid carcinoma: a national database study in Japan","volume":"109","author":"Toda","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070712532795200_bib20","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1111\/his.13942","article-title":"Mutational profiling of poorly differentiated and anaplastic thyroid carcinoma by the use of targeted next-generation sequencing","volume":"75","author":"Duan","year":"2019","journal-title":"Histopathology"},{"key":"2026070712532795200_bib21","doi-asserted-by":"crossref","first-page":"4238","DOI":"10.1158\/0008-5472.CAN-05-0047","article-title":"Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation","volume":"65","author":"Knauf","year":"2005","journal-title":"Cancer Res"},{"key":"2026070712532795200_bib22","doi-asserted-by":"crossref","first-page":"E1600","DOI":"10.1073\/pnas.1404357111","article-title":"p53 constrains progression to anaplastic thyroid carcinoma in a braf -mutant mouse model of papillary thyroid cancer","volume":"111","author":"McFadden","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026070712532795200_bib23","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1158\/1541-7786.MCR-23-0144","article-title":"Telomerase upregulation induces progression of mouse BrafV600E-driven thyroid cancers and triggers nontelomeric effects","volume":"21","author":"Landa","year":"2023","journal-title":"Mol Cancer Res"},{"key":"2026070712532795200_bib24","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1158\/1541-7786.MCR-14-0158-T","article-title":"Activating BRAF and PIK3CA mutations cooperate to promote anaplastic thyroid carcinogenesis","volume":"12","author":"Charles","year":"2014","journal-title":"Mol Cancer Res"},{"key":"2026070712532795200_bib25","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41574-023-00920-6","article-title":"Genomic alterations in thyroid cancer: biological and clinical insights","volume":"20","author":"Landa","year":"2024","journal-title":"Nat Rev Endocrinol"},{"key":"2026070712532795200_bib26","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/s41392-023-01705-z","article-title":"Targeting the RAS\/RAF\/MAPK pathway for cancer therapy: from mechanism to clinical studies","volume":"8","author":"Bahar","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"2026070712532795200_bib27","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ceb.2009.01.013","article-title":"Role of MAPK pathway oncoproteins in thyroid cancer pathogenesis and as drug targets","volume":"21","author":"Knauf","year":"2009","journal-title":"Curr Opin Cell Biol"},{"key":"2026070712532795200_bib28","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1158\/2326-6066.CIR-16-0177","article-title":"Kinase regulation of human MHC class I molecule expression on cancer cells","volume":"4","author":"Brea","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"2026070712532795200_bib29","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1158\/0008-5472.CAN-04-3314","article-title":"Conditional BRAFV600E expression induces DNA synthesis, apoptosis, dedifferentiation, and chromosomal instability in thyroid PCCL3 cells","volume":"65","author":"Mitsutake","year":"2005","journal-title":"Cancer Res"},{"key":"2026070712532795200_bib30","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/s41568-023-00598-y","article-title":"Pathogenesis of cancers derived from thyroid follicular cells","volume":"23","author":"Fagin","year":"2023","journal-title":"Nat Rev Cancer"},{"key":"2026070712532795200_bib31","doi-asserted-by":"crossref","first-page":"6034","DOI":"10.1158\/1078-0432.CCR-14-0879","article-title":"MHC class I loss is a frequent mechanism of immune escape in papillary thyroid cancer that is reversed by interferon and selumetinib treatment in vitro","volume":"20","author":"Angell","year":"2014","journal-title":"Clin Cancer Res"},{"key":"2026070712532795200_bib32","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1089\/thy.2014.0134","article-title":"BRAF V600E in papillary thyroid carcinoma is associated with increased programmed death ligand 1 expression and suppressive immune cell infiltration","volume":"24","author":"Angell","year":"2014","journal-title":"Thyroid"},{"key":"2026070712532795200_bib33","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1038\/s41467-022-29000-5","article-title":"Targeting myeloid derived suppressor cells reverts immune suppression and sensitizes BRAF-mutant papillary thyroid cancer to MAPK inhibitors","volume":"13","author":"Zhang","year":"2022","journal-title":"Nat Commun"},{"key":"2026070712532795200_bib34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0054302","article-title":"Genetic and pharmacological targeting of CSF-1\/CSF-1R inhibits tumor-associated macrophages and impairs BRAF-induced thyroid cancer progression","volume":"8","author":"Ryder","year":"2013","journal-title":"PLoS One"},{"key":"2026070712532795200_bib35","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1677\/ERC-08-0036","article-title":"Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer","volume":"15","author":"Ryder","year":"2008","journal-title":"Endocr Relat Cancer"},{"key":"2026070712532795200_bib36","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0022567","article-title":"Tumor-associated macrophages (TAMs) form an interconnected cellular supportive network in anaplastic thyroid carcinoma","volume":"6","author":"Caillou","year":"2011","journal-title":"PLoS One"},{"key":"2026070712532795200_bib37","article-title":"An integrated single-cell and spatial transcriptomic atlas of thyroid cancer progression identifies prognostic fibroblast subpopulations","author":"Loberg","year":"2025","journal-title":"bioRxiv"},{"key":"2026070712532795200_bib38","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.1158\/0008-5472.CAN-10-4463","article-title":"Mutationally activated BRAFV600E elicits papillary thyroid cancer in the adult mouse","volume":"71","author":"Charles","year":"2011","journal-title":"Cancer Res"},{"key":"2026070712532795200_bib39","doi-asserted-by":"crossref","first-page":"5467","DOI":"10.1038\/sj.onc.1209527","article-title":"Thyroid targeting of the N-ras(Gln61Lys) oncogene in transgenic mice results in follicular tumors that progress to poorly differentiated carcinomas","volume":"25","author":"Vitagliano","year":"2006","journal-title":"Oncogene"},{"key":"2026070712532795200_bib40","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.ccr.2014.07.007","article-title":"Structure of the BRAF-MEK complex reveals a kinase activity independent role for BRAF in MAPK signaling","volume":"26","author":"Haling","year":"2014","journal-title":"Cancer Cell"},{"key":"2026070712532795200_bib41","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.ccell.2015.08.001","article-title":"BRAF mutants evade ERK-dependent feedback by different mechanisms that determine their sensitivity to pharmacologic inhibition","volume":"28","author":"Yao","year":"2015","journal-title":"Cancer Cell"},{"key":"2026070712532795200_bib42","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/nature08314","article-title":"A dimerization-dependent mechanism drives RAF catalytic activation","volume":"461","author":"Rajakulendran","year":"2009","journal-title":"Nature"},{"key":"2026070712532795200_bib43","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.ccr.2012.10.009","article-title":"Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas","volume":"22","author":"Lito","year":"2012","journal-title":"Cancer Cell"},{"key":"2026070712532795200_bib44","doi-asserted-by":"crossref","first-page":"7979","DOI":"10.1073\/pnas.0900343106","article-title":"Endogenous expression of Hras G12V induces developmental defects and neoplasms with copy number imbalances of the oncogene","volume":"106","author":"Chen","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026070712532795200_bib45","doi-asserted-by":"crossref","first-page":"3689","DOI":"10.1158\/0008-5472.CAN-09-0024","article-title":"Oncogenic kras requires simultaneous PI3K signaling to induce ERK activation and transform thyroid epithelial cells in vivo","volume":"69","author":"Miller","year":"2009","journal-title":"Cancer Res"},{"key":"2026070712532795200_bib46","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a031500","article-title":"Ras-specific GTPase-Activating proteins-structures, mechanisms, and interactions","volume":"9","author":"Scheffzek","year":"2019","journal-title":"Cold Spring Harb Perspect Med"},{"key":"2026070712532795200_bib47","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/nn792","article-title":"Neurofibromin regulates G protein\u2013stimulated adenylyl cyclase activity","volume":"5","author":"Tong","year":"2002","journal-title":"Nat Neurosci"},{"key":"2026070712532795200_bib48","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1200\/JCO.2013.49.6596","article-title":"Remarkable response to crizotinib in woman with anaplastic lymphoma kinase\u2013rearranged anaplastic thyroid carcinoma","volume":"33","author":"Godbert","year":"2015","journal-title":"J Clin Oncol"},{"key":"2026070712532795200_bib49","article-title":"Recurrent poorly differentiated thyroid cancer successfully treated with radiation and immunotherapy","volume":"3","author":"Hamidi","year":"2025","journal-title":"JCEM Case Rep"},{"key":"2026070712532795200_bib50","doi-asserted-by":"crossref","first-page":"424","DOI":"10.3390\/genes11040424","article-title":"RET gene fusions in malignancies of the thyroid and other tissues","volume":"11","author":"Santoro","year":"2020","journal-title":"Genes"},{"key":"2026070712532795200_bib51","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.cell.2014.09.050","article-title":"Integrated genomic characterization of papillary thyroid carcinoma","volume":"159","author":"Agrawal","year":"2014","journal-title":"Cell"},{"key":"2026070712532795200_bib52","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/s41392-021-00828-5","article-title":"Targeting PI3K\/Akt signal transduction for cancer therapy","volume":"6","author":"He","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"2026070712532795200_bib53","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.tibs.2011.03.006","article-title":"The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation","volume":"36","author":"Mendoza","year":"2011","journal-title":"Trends Biochem Sci"},{"key":"2026070712532795200_bib54","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40463-022-00558-w","article-title":"Introduction and expression of PIK3CAE545K in a papillary thyroid cancer BRAFV600E cell line leads to a dedifferentiated aggressive phenotype","volume":"51","author":"Pinto","year":"2022","journal-title":"J Otolaryngol Head Neck Surg"},{"key":"2026070712532795200_bib55","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1158\/0008-5472.CAN-17-1925","article-title":"Tipifarnib inhibits HRAS-driven dedifferentiated thyroid cancers","volume":"78","author":"Untch","year":"2018","journal-title":"Cancer Res"},{"key":"2026070712532795200_bib56","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0002-9440(10)64577-4","article-title":"Loss of p53 promotes anaplasia and local invasion in ret\/PTC1-Induced thyroid carcinomas","volume":"157","author":"La Perle","year":"2000","journal-title":"Am J Pathol"},{"key":"2026070712532795200_bib57","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1089\/thy.2019.0284","article-title":"Mouse model of thyroid cancer progression and dedifferentiation driven by STRN-ALK expression and loss of p53: evidence for the existence of two types of poorly differentiated carcinoma","volume":"29","author":"Nikitski","year":"2019","journal-title":"Thyroid"},{"key":"2026070712532795200_bib58","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1172\/JCI120966","article-title":"Hgf\/met activation mediates resistance to BRAF inhibition in murine anaplastic thyroid cancers","volume":"128","author":"Knauf","year":"2018","journal-title":"J Clin Investig"},{"key":"2026070712532795200_bib59","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1038\/onc.2015.253","article-title":"TSH overcomes BrafV600E-induced senescence to promote tumor progression via downregulation of p53 expression in papillary thyroid cancer","volume":"35","author":"Zou","year":"2016","journal-title":"Oncogene"},{"key":"2026070712532795200_bib60","doi-asserted-by":"crossref","first-page":"15155","DOI":"10.1073\/pnas.1417549111","article-title":"Loss of p53 induces cell proliferation via ras-independent activation of the Raf\/Mek\/Erk signaling pathway","volume":"111","author":"Drosten","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026070712532795200_bib61","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrc.2015.4","article-title":"DNA repair, genome stability and cancer: a historical perspective","volume":"16","author":"Jeggo","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"2026070712532795200_bib62","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ebiom.2016.04.017","article-title":"Implications of genetic and epigenetic alterations of CDKN2A (p16 INK4a) in cancer","volume":"8","author":"Zhao","year":"2016","journal-title":"EBioMedicine"},{"key":"2026070712532795200_bib63","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1530\/ERC-13-0210","article-title":"Highly prevalent TERT promoter mutations in aggressive thyroid cancers","volume":"20","author":"Liu","year":"2013","journal-title":"Endocr Relat Cancer"},{"key":"2026070712532795200_bib64","doi-asserted-by":"crossref","first-page":"E1562","DOI":"10.1210\/jc.2013-2383","article-title":"Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease","volume":"98","author":"Landa","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070712532795200_bib65","doi-asserted-by":"crossref","first-page":"E632","DOI":"10.1210\/jc.2014-3606","article-title":"Association of TERT promoter mutation 1,295,228 C&gt;T with BRAF V600E mutation, older patient age, and distant metastasis in anaplastic thyroid cancer","volume":"100","author":"Shi","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070712532795200_bib66","doi-asserted-by":"crossref","first-page":"E754","DOI":"10.1210\/jc.2013-3734","article-title":"TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas","volume":"99","author":"Melo","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070712532795200_bib67","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1200\/JCO.2014.55.5094","article-title":"BRAF V600E and TERT promoter mutations cooperatively identify the Most aggressive papillary thyroid cancer with highest recurrence","volume":"32","author":"Xing","year":"2014","journal-title":"J Clin Oncol"},{"key":"2026070712532795200_bib68","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/cen.14316","article-title":"The predictive value of coexisting BRAFV600E and TERT promoter mutations on poor outcomes and high tumour aggressiveness in papillary thyroid carcinoma: a systematic review and meta-analysis","volume":"94","author":"Chen","year":"2021","journal-title":"Clin Endocrinol"},{"key":"2026070712532795200_bib69","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1002\/cncr.29934","article-title":"Prognostic effects of TERT promoter mutations are enhanced by coexistence with BRAF or RAS mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients","volume":"122","author":"Song","year":"2016","journal-title":"Cancer"},{"key":"2026070712532795200_bib70","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/gcc.22928","article-title":"Characterization of TERT and BRAF copy number variation in papillary thyroid carcinoma: an analysis of the cancer genome atlas study","volume":"60","author":"McKelvey","year":"2021","journal-title":"Genes Chromosomes Cancer"},{"key":"2026070712532795200_bib71","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1001","article-title":"Comprehensive molecular analysis of immortalization hallmarks in thyroid cancer reveals new prognostic markers","volume":"12","author":"Montero-Conde","year":"2022","journal-title":"Clin Transl Med"},{"key":"2026070712532795200_bib72","doi-asserted-by":"crossref","first-page":"6172","DOI":"10.1038\/s41388-019-0872-9","article-title":"Mechanisms underlying the activation of TERT transcription and telomerase activity in human cancer: old actors and new players","volume":"38","author":"Yuan","year":"2019","journal-title":"Oncogene"},{"key":"2026070712532795200_bib73","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/nrc3025","article-title":"Telomeric and extra-telomeric roles for telomerase and the telomere-binding proteins","volume":"11","author":"Mart\u00ednez","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"2026070712532795200_bib74","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adg7125","article-title":"TERT accelerates BRAF mutant\u2013induced thyroid cancer dedifferentiation and progression by regulating ribosome biogenesis","volume":"9","author":"Yu","year":"2023","journal-title":"Sci Adv"},{"key":"2026070712532795200_bib75","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1530\/ERC-17-0562","article-title":"Interaction of BRAF-induced ETS factors with mutant TERT promoter in papillary thyroid cancer","volume":"26","author":"Song","year":"2019","journal-title":"Endocr Relat Cancer"},{"key":"2026070712532795200_bib76","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/2159-8290.CD-18-0606","article-title":"EIF1AX and RAS mutations cooperate to drive thyroid tumorigenesis through ATF4 and c-MYC","volume":"9","author":"Krishnamoorthy","year":"2019","journal-title":"Cancer Discov"},{"key":"2026070712532795200_bib77","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/s41392-019-0095-0","article-title":"Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials","volume":"4","author":"Cheng","year":"2019","journal-title":"Signal Transduct Target Ther"},{"key":"2026070712532795200_bib78","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41571-020-0357-3","article-title":"The SWI\/SNF complex in cancer \u2013 biology, biomarkers and therapy","volume":"17","author":"Mittal","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"2026070712532795200_bib79","doi-asserted-by":"crossref","first-page":"680","DOI":"10.3390\/cancers12030680","article-title":"Global RNA expression and DNA methylation patterns in primary anaplastic thyroid cancer","volume":"12","author":"Ravi","year":"2020","journal-title":"Cancers"},{"key":"2026070712532795200_bib80","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1089\/thy.2006.16.633","article-title":"CpG Island methylation of tumor-related promoters occurs preferentially in undifferentiated carcinoma","volume":"16","author":"Schagdarsurengin","year":"2006","journal-title":"Thyroid"},{"key":"2026070712532795200_bib81","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1002\/cncr.23869","article-title":"Association of PTEN gene methylation with genetic alterations in the phosphatidylinositol 3-kinase\/AKT signaling pathway in thyroid tumors","volume":"113","author":"Hou","year":"2008","journal-title":"Cancer"},{"key":"2026070712532795200_bib82","first-page":"2316","article-title":"Methylation of the thyroid-stimulating hormone receptor gene in epithelial thyroid tumors: a marker of malignancy and a cause of gene silencing","volume":"63","author":"Xing","year":"2003","journal-title":"Cancer Res"},{"key":"2026070712532795200_bib83","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1158\/2159-8290.CD-20-0735","article-title":"SWI\/SNF complex mutations promote thyroid tumor progression and insensitivity to redifferentiation therapies","volume":"11","author":"Saqcena","year":"2021","journal-title":"Cancer Discov"},{"key":"2026070712532795200_bib84","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.ccell.2020.03.010","article-title":"Mechanisms of sensitivity and resistance to CDK4\/6 inhibition","volume":"37","author":"\u00c1lvarez-Fern\u00e1ndez","year":"2020","journal-title":"Cancer Cell"},{"key":"2026070712532795200_bib85","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"key":"2026070712532795200_bib86","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1001\/jama.2023.26348","article-title":"Thyroid cancer","volume":"331","author":"Boucai","year":"2024","journal-title":"JAMA"},{"key":"2026070712532795200_bib87","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.annonc.2021.12.014","article-title":"Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study","volume":"33","author":"Subbiah","year":"2022","journal-title":"Ann Oncol"},{"key":"2026070712532795200_bib88","doi-asserted-by":"crossref","first-page":"4618","DOI":"10.1158\/1078-0432.CCR-21-2138","article-title":"Molecular pathways and mechanisms of BRAF in cancer therapy","volume":"28","author":"Poulikakos","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2026070712532795200_bib89","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.ccell.2016.06.024","article-title":"An integrated model of RAF inhibitor action predicts inhibitor activity against oncogenic BRAF signaling","volume":"30","author":"Karoulia","year":"2016","journal-title":"Cancer Cell"},{"key":"2026070712532795200_bib90","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nature08833","article-title":"RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth","volume":"464","author":"Hatzivassiliou","year":"2010","journal-title":"Nature"},{"key":"2026070712532795200_bib91","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/nature08902","article-title":"RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF","volume":"464","author":"Poulikakos","year":"2010","journal-title":"Nature"},{"key":"2026070712532795200_bib92","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/nchembio.1257","article-title":"Inhibitors that stabilize a closed RAF kinase domain conformation induce dimerization","volume":"9","author":"Lavoie","year":"2013","journal-title":"Nat Chem Biol"},{"key":"2026070712532795200_bib93","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1158\/2159-8290.CD-12-0531","article-title":"Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF -Mutant thyroid carcinomas","volume":"3","author":"Montero-Conde","year":"2013","journal-title":"Cancer Discov"},{"key":"2026070712532795200_bib94","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/s12943-022-01676-9","article-title":"Yap governs a lineage-specific neuregulin1 pathway-driven adaptive resistance to RAF kinase inhibitors","volume":"21","author":"Garcia-Rendueles","year":"2022","journal-title":"Mol Cancer"},{"key":"2026070712532795200_bib95","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/S1470-2045(18)30497-2","article-title":"Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial","volume":"19","author":"Dummer","year":"2018","journal-title":"Lancet Oncol"},{"key":"2026070712532795200_bib96","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMoa1502309","article-title":"Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations","volume":"373","author":"Hyman","year":"2015","journal-title":"N Engl J Med"},{"key":"2026070712532795200_bib97","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41571-023-00852-0","article-title":"BRAF \u2013 a tumour-agnostic drug target with lineage-specific dependencies","volume":"21","author":"Hanrahan","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"2026070712532795200_bib98","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1089\/thy.2019.0514","article-title":"Acquired secondary RAS mutation in BRAF V600E -mutated thyroid cancer patients treated with BRAF inhibitors","volume":"30","author":"Cabanillas","year":"2020","journal-title":"Thyroid"},{"key":"2026070712532795200_bib99","first-page":"R173","article-title":"Molecular mechanisms of resistance to kinase inhibitors in thyroid cancers","volume":"29","author":"Hofmann","year":"2022","journal-title":"Endocr Relat Cancer"},{"key":"2026070712532795200_bib100","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1158\/1541-7786.MCR-21-0442","article-title":"Genomic and transcriptomic correlates of thyroid carcinoma evolution after BRAF inhibitor therapy","volume":"20","author":"Lee","year":"2022","journal-title":"Mol Cancer Res"},{"key":"2026070712532795200_bib101","doi-asserted-by":"crossref","first-page":"30907","DOI":"10.18632\/oncotarget.9023","article-title":"Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model","volume":"7","author":"Danysh","year":"2016","journal-title":"Oncotarget"},{"key":"2026070712532795200_bib102","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2023.104634","article-title":"Structure and RAF family kinase isoform selectivity of type II RAF inhibitors tovorafenib and naporafenib","volume":"299","author":"Tkacik","year":"2023","journal-title":"J Biol Chem"},{"key":"2026070712532795200_bib103","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1158\/1078-0432.CCR-20-2563","article-title":"LXH254, a potent and selective ARAF-sparing inhibitor of BRAF and CRAF for the treatment of MAPK-driven tumors","volume":"27","author":"Monaco","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2026070712532795200_bib104","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41586-021-03515-1","article-title":"ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma","volume":"594","author":"Yen","year":"2021","journal-title":"Nature"},{"key":"2026070712532795200_bib105","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1200\/JCO.22.02018","article-title":"Initial evidence for the efficacy of naporafenib in combination with trametinib in NRAS -Mutant melanoma: results from the expansion arm of a phase Ib, open-label study","volume":"41","author":"de Braud","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026070712532795200_bib106","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1200\/JCO.2021.39.15_suppl.3007","article-title":"A phase Ib trial of belvarafenib in combination with cobimetinib in patients with advanced solid tumors: interim results of dose-escalation and patients with NRAS-Mutant melanoma of dose-expansion","volume":"39","author":"Shin","year":"2021","journal-title":"J Clin Oncol"},{"key":"2026070712532795200_bib107","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.107964","article-title":"A phase Ib study of the combination of naporafenib with rineterkib or trametinib in patients with advanced and metastatic KRAS- or BRAF-mutant non-small cell lung cancer","volume":"197","author":"Planchard","year":"2024","journal-title":"Lung Cancer"},{"key":"2026070712532795200_bib108","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/s41591-023-02668-y","article-title":"The type II RAF inhibitor tovorafenib in relapsed\/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial","volume":"30","author":"Kilburn","year":"2024","journal-title":"Nat Med"},{"key":"2026070712532795200_bib109","article-title":"Understanding and overcoming innate and acquired MAPK-inhibition resistance in anaplastic thyroid cancer","author":"Zeng","year":"2024","journal-title":"medRxiv"},{"key":"2026070712532795200_bib110","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s12885-019-5380-3","article-title":"Safety and antitumor activity of the anti\u2013PD-1 antibody pembrolizumab in patients with advanced, PD-L1\u2013positive papillary or follicular thyroid cancer","volume":"19","author":"Mehnert","year":"2019","journal-title":"BMC Cancer"},{"key":"2026070712532795200_bib111","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1002\/cncr.34657","article-title":"Efficacy and safety of pembrolizumab monotherapy in patients with advanced thyroid cancer in the phase 2 KEYNOTE-158 study","volume":"129","author":"Oh","year":"2023","journal-title":"Cancer"},{"key":"2026070712532795200_bib112","doi-asserted-by":"crossref","DOI":"10.1172\/JCI169653","article-title":"Anaplastic transformation in thyroid cancer revealed by single-cell transcriptomics","volume":"133","author":"Lu","year":"2023","journal-title":"J Clin Investig"},{"key":"2026070712532795200_bib113","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abf3657","article-title":"Characterizing dedifferentiation of thyroid cancer by integrated analysis","volume":"7","author":"Luo","year":"2021","journal-title":"Sci Adv"},{"key":"2026070712532795200_bib114","article-title":"A spatially resolved transcriptome landscape during thyroid cancer progression","volume":"6","author":"Liao","year":"2025","journal-title":"Cell Rep Med"},{"key":"2026070712532795200_bib115","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.173712","article-title":"Distinct tumor microenvironment makes anaplastic thyroid cancer more lethal but immunotherapy-sensitive than papillary thyroid cancer","volume":"9","author":"Han","year":"2024","journal-title":"JCI Insight"},{"key":"2026070712532795200_bib116","article-title":"Loss of tumor cell MHC class II drives insensitivity of BRAF-mutant anaplastic thyroid cancers to MAPK inhibitors","author":"Tiedje","year":"2025","journal-title":"bioRxiv"},{"key":"2026070712532795200_bib117","first-page":"3557","article-title":"Immune profiling of thyroid carcinomas suggests the existence of two major phenotypes: an ATC-like and a PDTC-like","volume":"104","author":"Giannini","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070712532795200_bib118","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1200\/JCO.19.02727","article-title":"PD-1 blockade in anaplastic thyroid carcinoma","volume":"38","author":"Capdevila","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026070712532795200_bib119","doi-asserted-by":"crossref","first-page":"S1294","DOI":"10.1016\/j.annonc.2022.07.1725","article-title":"1645O Durvalumab (D) plus tremelimumab (T) for the treatment of patients with progressive, refractory advanced thyroid carcinoma: the DUTHY (GETNE-T1812) trial","volume":"33","author":"Capdevila Castillon","year":"2022","journal-title":"Ann Oncol"},{"key":"2026070712532795200_bib120","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1001\/jamaoncol.2024.4019","article-title":"Dual immune checkpoint inhibition in patients with aggressive thyroid carcinoma","volume":"10","author":"Sehgal","year":"2024","journal-title":"JAMA Oncol"},{"key":"2026070712532795200_bib121","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41573-019-0044-1","article-title":"The great escape: tumour cell plasticity in resistance to targeted therapy","volume":"19","author":"Boumahdi","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"2026070712532795200_bib122","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1089\/thy.2023.0573","article-title":"Checkpoint inhibition in addition to dabrafenib\/trametinib for BRAF V600E -Mutated anaplastic thyroid carcinoma","volume":"34","author":"Hamidi","year":"2024","journal-title":"Thyroid"}],"container-title":["European Thyroid Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/etj.bioscientifica.com\/view\/journals\/etj\/14\/3\/ETJ-25-0057.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/etj.bioscientifica.com\/downloadpdf\/journals\/etj\/14\/3\/ETJ-25-0057.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/etj\/article-pdf\/doi\/10.1530\/ETJ-25-0057\/32642\/etj-25-0057.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/etj\/article-pdf\/doi\/10.1530\/ETJ-25-0057\/32642\/etj-25-0057.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T17:22:03Z","timestamp":1783444923000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/etj\/article\/14\/3\/e250057\/4380\/NOVEL-INSIGHTS-IN-ADVANCED-THYROID-CARCINOMA-FROM"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,21]]},"references-count":122,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6,1]]}},"URL":"https:\/\/doi.org\/10.1530\/etj-25-0057","relation":{},"ISSN":["2235-0802","2235-0640"],"issn-type":[{"value":"2235-0802","type":"electronic"},{"value":"2235-0640","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,21]]},"article-number":"e250057"}}